J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets

Johnson & Johnson's pharmaceutical division, Janssen, represents one of the most successful franchises in the history of biotechnology. Janssen has historically built its revenue base on high-barrier, large-molecule specialty therapeutics in immunology and oncology. However, as the patent walls on its multi-billion-dollar immunology blockbuster Stelara (ustekinumab) crumble, J&J is executing a high-stakes transition.

The company is employing a multi-layered commercial strategy: defending its immunology market share by transitioning patients from Stelara to Tremfya (guselkumab), protecting its oncology revenue by converting intravenous (IV) infusions to subcutaneous (SC) formulations (such as Darzalex Faspro), and commercializing advanced cell and gene therapies (like Carvykti).

For commercial payers, medical directors, and specialty benefit managers, J&J's portfolio presents complex utilization challenges. Many of its core assets are administered in clinical settings and billed under the medical benefit, meaning that simple retail pharmacy tier exclusions are ineffective. Grounded in systematic queries of the FDA Purple Book, FDA Orange Book, CMS National Average Drug Acquisition Cost (NADAC) registry, FDA Enforcement Reports, and ClinicalTrials.gov registry, this portfolio dossier analyzes J&J's biopharmaceutical assets, quantifies the Stelara LOE impact, details specialty reimbursement codes, and outlines management rules for payers.

---

Executive Summary & Scenario Analysis

To align on the clinical and economic implications of J&J's post-Stelara portfolio, we must address the primary questions facing clinical pharmacy directors, health system purchasing teams, and benefit designers.

Scenario Question

What does public regulatory and pricing data reveal about J&J's portfolio transition post-Stelara exclusivity, and how should payer contracting teams respond?

Direct Answer

With Stelara (ustekinumab) losing exclusivity in January 2025, J&J is actively shifting its immunology base to Tremfya (guselkumab) while managing oncology blockbusters Darzalex and Carvykti. The Purple Book shows 15 unique reference 351(a) BLAs (including Stelara BLA 125261, Tremfya BLA 761061, and the newly approved Imaavy BLA 761430 for nipocalimab-aahu) and zero biosimilar 351(k) BLAs. Meanwhile, J&J has a small-molecule legacy in the Orange Book with 137 unique approved applications (115 NDAs and 22 ANDAs). Payers must prepare for biosimilar ustekinumab (like Wezlana) to capture Stelara's massive unit price ($29,794.54 per 90 MG/ML syringe in CMS NADAC), while restricting Tremfya to prevent high-cost brand shifting.

---

Managing the Stelara Patent Cliff: Biosimilar Ustekinumab Competitors

The most significant near-term financial event for J&J is the loss of exclusivity for Stelara (ustekinumab, BLA 125261 and BLA 761044). Approved under the 351(a) pathway, Stelara has generated over $10 billion in annual global revenue, serving as a cornerstone therapy for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

• Mechanism of Action: Ustekinumab is a human IgG1/kappa monoclonal antibody that binds with high affinity and specificity to the shared p40 protein subunit of human interleukin-12 (IL-12) and interleukin-23 (IL-23) cytokines. By preventing these cytokines from binding to their IL-12R-beta-1 receptor protein on the surface of immune cells, ustekinumab blocks the downstream signaling pathways that drive T-helper cell (Th1 and Th17) differentiation and cytokine release.
• The Patent Settlement: J&J engaged in extensive patent litigation to protect Stelara's formulation and method-of-use patents. In 2023, J&J reached settlement agreements with several biosimilar developers—led by Amgen (Wezlana), Alvotech/Teva (Pyzchiva), and Celltrion (Steqeyma)—delaying their launch until January 1, 2025. On this date, Amgen launched Wezlana as the first interchangeable ustekinumab biosimilar in the United States, followed shortly by Teva/Alvotech's launch of Pyzchiva in mid-2025.
• CMS NADAC Baseline Pricing: An analysis of the June 10, 2026 CMS NADAC registry illustrates the massive baseline cost of branded Stelara prior to generic erosion:
  • Stelara 90 MG/ML Syringe (1 mL): $29,794.54472 per mL (≈ $29,794.54 per 90 mg dose)
  • Stelara 45 MG/0.5 ML Syringe (0.5 mL): $29,841.64800 per mL (≈ $14,920.82 per 45 mg dose)
• Formulary Actions for Payers: Because Stelara represents a massive specialty pharmacy cost driver, payers must execute a Biosimilar Transition Strategy:
  1. Mandatory Biosimilar Substitution: PBMs should immediately position interchangeable ustekinumab biosimilars (like Wezlana) as the preferred agents on commercial formularies, moving branded Stelara to an excluded status.
  2. Capture PBM Co-Branded / Private Label Savings: Payers should leverage PBM private labels (such as CVS Caremark's co-branded Pyzchiva or Express Scripts' Quallent-affiliated versions) which offer discounts exceeding 60-80% off Stelara's WAC.

Comparison Table: Ustekinumab Biosimilars

The table below summarizes the key ustekinumab biosimilars cleared or approved for commercialization, referencing their BLA approvals and clinical trial parameters:

Clinical Trial Equivalence and Interchangeability Parameters

To secure an Interchangeable Designation under the Biologics Price Competition and Innovation Act (BPCIA), Amgen's Wezlana program had to meet rigorous clinical switching standards. The program demonstrated that the biosimilar can be expected to produce the same clinical result as Stelara in any given patient. Furthermore, for a product administered more than once, the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar and Stelara is not greater than the risk of using Stelara without such switching.

• Pharmacokinetic Similarity: The pharmacokinetic (PK) profile was evaluated in healthy volunteers, confirming bioequivalence. The geometric mean ratios for maximum serum concentration ($C_{\max}$) and area under the curve ($AUC_{0-\infty}$) fell strictly within the standard regulatory acceptance interval of 80.00% to 125.00%.
• The Switching Trial Design: Patients with moderate-to-severe plaque psoriasis were randomized to receive either Stelara or Wezlana. At Week 12, patients in the switching group underwent multiple transitions (Stelara to Wezlana, Wezlana to Stelara, and back to Wezlana) over a 52-week period. The primary clinical efficacy endpoint was the percentage change from baseline in the Psoriasis Area and Severity Index (PASI) score at Week 12. The 95% confidence interval for the treatment difference was fully contained within the pre-specified equivalence margin of -10% to 10%, demonstrating no clinical divergence between the cohorts.

Shifting the Immunology Base to Tremfya (guselkumab, BLA 761061)

To protect its market share from ustekinumab biosimilars, J&J is actively shifting patients to Tremfya (guselkumab), which is protected by patents extending into the 2030s.

• Mechanism of Action: Unlike Stelara, which blocks both IL-12 and IL-23 by binding the shared p40 subunit, Tremfya is a human monoclonal IgG1/lambda antibody that binds selectively to the p19 subunit of the IL-23 cytokine only. This selective inhibition blocks IL-23 signaling without affecting IL-12, which some clinical models suggest offers a more targeted anti-inflammatory effect in psoriasis and inflammatory bowel disease while preserving IL-12-dependent host defense mechanisms.
• Clinical Foundation (GALAXI & QUASAR Trials): J&J expanded Tremfya's label to include inflammatory bowel disease based on two key clinical packages:
  • GALAXI (Crohn's Disease): In a Phase III trial evaluating patients with moderately to severely active Crohn's disease, Tremfya demonstrated superior clinical remission rates compared to placebo, with subcutaneous maintenance dosing (every 8 weeks) achieving sustained mucosal healing.
  • QUASAR (Ulcerative Colitis): In moderately to severely active UC patients, Tremfya induction (either IV or SC) followed by subcutaneous maintenance resulted in statistically significant clinical remission and endoscopic response compared to placebo.
• Payer Strategy: To prevent J&J from executing a non-value-added "brand shift" (where patients are moved from cheap biosimilar ustekinumab to expensive brand Tremfya), payers must implement strict prior authorizations. Tremfya should be restricted to patients who have documented clinical failure on preferred, lower-cost biosimilar ustekinumab or adalimumab. For detailed coverage criteria and step-therapy rules, refer to our comparison of Stelara biosimilars and our Stelara coverage guide.

Tremfya Dosing Regimens by Indication

Clinical pharmacy teams must audit the prescribed dosing intervals to ensure alignment with FDA-approved labels:

1. Plaque Psoriasis & Psoriatic Arthritis: 100 mg administered subcutaneously at Week 0, Week 4, and every 8 weeks thereafter.
2. Crohn's Disease:
   • Indication Induction: 200 mg intravenously at Week 0, Week 4, and Week 8 (administered under the medical benefit).
   • Maintenance Therapy: 100 mg subcutaneously at Week 12 and every 8 weeks thereafter (managed under the pharmacy benefit). Alternatively, a high-dose maintenance option of 200 mg subcutaneously every 8 weeks is indicated for patients with inadequate response.
3. Ulcerative Colitis:
   • Indication Induction: 200 mg intravenously at Week 0, Week 4, and Week 8.
   • Maintenance Therapy: 100 mg subcutaneously at Week 12 and every 8 weeks thereafter.

Prior Authorization Decision Tree for Tremfya (guselkumab)

To manage immunology specialty spend, payers should enforce the following Formulary Utilization Tree:

[Prescriber Submits Tremfya Request]
                 |
                 v
[Has patient tried preferred biosimilar adalimumab or ustekinumab?]
                 |
                 +---> NO: Deny / Require 90-day trial of Wezlana or Pyzchiva
                 |
                 +---> YES: Move to Clinical Indication Verification
                                |
                                v
[Is diagnosis moderate-to-severe Crohn's, UC, or Plaque Psoriasis?]
                                |
                                +---> NO: Deny / Require clinical justification
                                +---> YES: Approve for 12 months / Limit to Q8W dosing

1. Trial of Preferred Biosimilars: The patient must have documented clinical failure, intolerance, or medical contraindication to a preferred 351(k) biosimilar ustekinumab (Wezlana or Pyzchiva) or a preferred adalimumab biosimilar.
2. Dosing Frequency Limits: Maintenance dosing must be restricted to 100 mg administered subcutaneously every 8 weeks. Any requests for accelerated dosing (e.g., every 4 weeks) must require documentation of secondary loss of response with therapeutic drug monitoring showing low trough concentrations.

The SEQUENCE Study: Head-to-Head Comparative Trial Data

To defend its immunology market share against competitor IL-23 blockers, particularly AbbVie's Skyrizi (risankizumab), J&J funded head-to-head clinical trials. In the SEQUENCE study (NCT04919109) evaluating patients with moderately to severely active Crohn's disease who had previously failed TNF antagonist therapy, Skyrizi was compared directly to Stelara.

The trial results demonstrated that risankizumab achieved clinical remission non-inferiority and endoscopic remission superiority compared to ustekinumab at Week 48. Specifically, endoscopic remission was achieved in 32% of risankizumab-treated patients compared to only 16% of ustekinumab-treated patients (p < 0.0001).

This clinical superiority has driven PBMs to exclude Stelara and prioritize Skyrizi, forcing J&J to focus on Tremfya's unique selective p19 inhibition profile to regain therapeutic positioning. Payers should leverage these head-to-head metrics to negotiate higher discounts from J&J on Tremfya.

---

Oncology Growth Drivers: Darzalex Faspro and Carvykti Reimbursement

J&J's oncology franchise is centered on multiple myeloma, where the company utilizes subcutaneous reformulations and cellular immunotherapies to defend its market leadership.

1. Darzalex Faspro (daratumumab and hyaluronidase-fihj, BLA 761145)

• Innovator Target: Original Darzalex IV (daratumumab, BLA 761036)
• Mechanism of Action: Daratumumab is an IgG1/kappa monoclonal antibody that binds to the CD38 glycoprotein overexpressed on multiple myeloma cells. It induces tumor cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).
• Subcutaneous Formulation Strategy: Original Darzalex was administered as a lengthy IV infusion (often taking 3 to 7 hours), which represented a major bottleneck for infusion centers and a burden for patients. To address this, J&J developed Darzalex Faspro, combining daratumumab with recombinant human hyaluronidase PH20 (which temporarily depolymerizes hyaluronan in the subcutaneous tissue, allowing for rapid absorption of large-volume injections).
• Clinical Foundation (The COLUMBA Trial): The subcutaneous formulation was approved based on the Phase III COLUMBA trial (NCT03277105), which demonstrated non-inferiority in objective response rate and pharmacokinetic trough levels compared to IV daratumumab. Crucially, the injection time was reduced to 3 to 5 minutes, and the rate of infusion-related reactions fell from 34% to 13%.
• Medical Billing & Reimbursement: Darzalex Faspro is administered by healthcare professionals and billed under the medical benefit. Its assigned HCPCS code is J9144 (Injection, daratumumab, 10 mg and hyaluronidase-fihj), where 1 billable unit = 10 mg. A standard dose of 1,800 mg requires billing 180 units per administration.
• Formulary Control: By successfully transitioning over 80% of its daratumumab patients to the subcutaneous J9144 formulation, J&J has protected the franchise from upcoming IV daratumumab biosimilars. Payers must monitor J9144 usage and ensure that medical benefit policies require clinical documentation of multiple myeloma staging before authorizing treatment. For a detailed breakdown of the IV-to-SC oncology transition, refer to our Darzalex SC vs IV biosimilar tracker.

2. Rybrevant (amivantamab-vmjw, BLA 761210) & Lazertinib combination

To establish a dominant footprint in non-small cell lung cancer (NSCLC), J&J is commercializing Rybrevant (amivantamab-vmjw) in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib.

• Mechanism of Action: Amivantamab is a bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition receptor (MET). It binds to these receptors simultaneously, blocking ligand binding and promoting receptor internalization and degradation. Lazertinib is an oral, brain-penetrant EGFR TKI that binds irreversibly to mutant forms of EGFR. The combination targets EGFR signaling from both extracellular (Rybrevant) and intracellular (lazertinib) domains.
• Clinical Trial Foundations:
  • The MARIPOSA Trial (First-Line EGFRm NSCLC): This Phase III study evaluated Rybrevant plus lazertinib against osimertinib monotherapy in treatment-naive EGFR-mutated (Exon 19 deletion or L858R) advanced NSCLC. The combination demonstrated a statistically significant improvement in progression-free survival (PFS), with a median PFS of 23.7 months compared to 16.6 months for the osimertinib arm (Hazard Ratio: 0.70; 95% CI: 0.58–0.85; p < 0.001).
  • The MARIPOSA-2 Trial (Post-Osimertinib Progression): This study evaluated Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) with or without lazertinib in EGFRm NSCLC patients who had progressed on or after osimertinib. The Rybrevant plus chemotherapy arm demonstrated a median PFS of 6.3 months compared to 4.2 months for chemotherapy alone (Hazard Ratio: 0.48; p < 0.001), representing a significant delay in disease progression.
• Specialty Management & Reimbursement: Rybrevant is billed under the medical benefit using HCPCS code J9061 (Injection, amivantamab-vmjw, 2 mg). A standard dose of 1,050 mg (for patients under 80 kg) requires billing 525 units per infusion, while a dose of 1,400 mg (for patients over 80 kg) requires 700 units. Because the combination has a higher rate of venous thromboembolism (VTE) and dermatological toxicity (rash, paronychia) compared to osimertinib alone, payers must verify that clinical teams have implemented appropriate prophylactic anticoagulation protocols (e.g., low-molecular-weight heparin) during the first 4 months of therapy.

3. Carvykti (ciltacabtagene autoleucel, BLA 125746)

• Indication: Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
• Mechanism of Action: Carvykti is an autologous Chimeric Antigen Receptor T-cell (CAR-T) therapy. It is genetically modified using a lentiviral vector to express a CAR targeting two distinct epitopes on the B-cell maturation antigen (BCMA) expressed on myeloma cells, T cells are then activated to lyse targets.
• Clinical Foundation (The CARTITUDE-4 Trial): Carvykti was approved in earlier lines of therapy based on the Phase III CARTITUDE-4 trial (NCT04181827), which compared a single infusion of Carvykti against standard-of-care comparator regimens (pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in lenalidomide-refractory multiple myeloma patients. The trial demonstrated a 74% reduction in the risk of disease progression or death (Hazard Ratio for PFS: 0.26; 95% CI: 0.18–0.38; p < 0.0001) for the Carvykti arm, with median PFS not reached compared to 11.8 months for the comparator arm. Overall survival also showed a statistically significant improvement.
• Safety Profile (CRS and ICANS Grading): In CARTITUDE-4, Cytokine Release Syndrome (CRS) occurred in 76% of patients, with Grade 3/4 CRS occurring in 1.1%. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was reported in 4.5% of patients. Payer policy teams must verify that treating facilities are certified under the Carvykti Risk Evaluation and Mitigation Strategy (REMS) program and have immediate access to tocilizumab (J3240) for CRS management.
• Billing Logistics: Carvykti is billed under the medical benefit using HCPCS code Q2056 (Ciltacabtagene autoleucel, up to 100 million autologous BCMA-directed CAR-positive T cells). Billed per therapeutic dose.
• Payer Management: With a list price exceeding $465,000, Carvykti is subject to intense review. Payers must verify that patients have progressed on lenalidomide and are treated at certified CAR-T infusion centers.

4. Imaavy (nipocalimab-aahu, BLA 761430)

• Indication: Treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years and older who are anti-AChR or anti-MuSK antibody positive.
• Mechanism of Action: Nipocalimab is a first-in-class monoclonal antibody that binds to and blocks the neonatal Fc receptor (FcRn). By blocking FcRn, Imaavy prevents the recycling of immunoglobulin G (IgG) antibodies, promoting their clearance and lowering circulating IgG levels, including pathogenic autoantibodies.
• Payer Strategy: Billed under the medical benefit. Prior authorizations must require documentation of anti-AChR or anti-MuSK antibody positivity and step therapy through standard immunosuppressants (mycophenolate mofetil or azathioprine).

Comparison Table: Neonatal Fc Receptor (FcRn) Inhibitors

Payers must evaluate the relative positioning of nipocalimab against established FcRn blockers in the gMG space:

---

Detailed Clinical Profiling of J&J Biological BLA Assets

J&J's biological leadership is established through 15 reference 351(a) BLA registrations in the FDA Purple Book. Below is a comprehensive clinical and molecular analysis of each active biologic:

1. Remicade (infliximab, BLA 103772)

• Indication: Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
• Mechanism of Action: Infliximab is a chimeric IgG1/kappa monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF-alpha, neutralizing its pro-inflammatory activity and inducing apoptosis of TNF-producing cells.
• Payer Management: Billed under the medical benefit using HCPCS code J1745 (Injection, infliximab, 10 mg). Payers have implemented biosimilar step therapy requiring preferred infliximab biosimilars (like Inflectra or Renflexis) to capture double-digit savings.

2. Simponi (golimumab, BLA 125289) and Simponi Aria (BLA 125433)

• Indication: Active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderately to severely active ulcerative colitis.
• Mechanism of Action: Golimumab is a human IgG1/kappa monoclonal antibody that targets and neutralizes TNF-alpha, preventing its binding to receptor complexes.
• Dosing Splits: Simponi is administered subcutaneously once monthly (pharmacy benefit), whereas Simponi Aria is administered intravenously every 8 weeks (medical benefit, billed under HCPCS code J1602).

3. Rybrevant (amivantamab-vmjw, BLA 761210)

• Indication: EGFR exon 20 insertion mutant NSCLC; or combined with lazertinib for first-line EGFR exon 19 del / L858R NSCLC.
• Mechanism of Action: Amivantamab is an EGFR-MET bispecific antibody that blocks ligand binding and promotes receptor internalization and degradation, while directing ADCC.
• Clinical Foundation (The MARIPOSA Trial): Rybrevant plus lazertinib reduced the risk of progression or death by 30% compared to osimertinib monotherapy (PFS: 23.7 months vs. 16.6 months; p < 0.001), establishing a new therapeutic standard in front-line EGFRm lung cancer. Billed under HCPCS code J9061.

4. Tecvayli (teclistamab-cqyv, BLA 761291)

• Indication: Relapsed or refractory multiple myeloma after 4 prior lines.
• Mechanism of Action: Teclistamab is a bispecific CD3 T-cell redirecting antibody that binds CD3 on T cells and BCMA on myeloma cells, inducing T-cell activation and tumor cell lysis.
• Clinical Foundation (MajesTEC-1 Trial): Reached an objective response rate of 63.0% in heavily pretreated patients, with a median duration of response of 18.4 months. Billed under HCPCS code J9380.

5. Talvey (talquetamab-tgvs, BLA 761342)

• Indication: Relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy.
• Mechanism of Action: Talquetamab is a first-in-class bispecific antibody targeting CD3 on T cells and G-protein coupled receptor class C group 5 member D (GPRC5D) on multiple myeloma cells, redirecting T-cell cytotoxicity.
• Clinical Foundation (MonumenTAL-1 Trial): Approved based on the MonumenTAL-1 study, showing an ORR of 73.0% to 74.1% depending on subcutaneous dosing intervals (weekly vs. bi-weekly). Billed under HCPCS code J9381.

6. Legacy and Mature Biologics (Orthoclone OKT3, Reopro)

• Orthoclone OKT3 (muromonab-CD3, BLA 103463): Historically approved in 1986 as the first monoclonal antibody for acute organ transplant rejection. Discontinued commercially but remains in Purple Book archives.
• Reopro (abciximab, BLA 103575): Historically approved as a platelet aggregation inhibitor for percutaneous coronary intervention. Discontinued commercially but represents J&J's early biologic history.

---

The Invega Franchise: Long-Acting Atypical Antipsychotic Billing

J&J has maintained commercial leadership in atypical antipsychotic therapies through its long-acting injectable (LAI) paliperidone palmitate franchise:

• Invega Sustenna (1-Month Injection): Dosed once monthly. Billed under HCPCS code J2426 (Injection, paliperidone palmitate, 1 mg).
• Invega Trinza (3-Month Injection): Dosed once every 3 months. Billed under HCPCS code J2426, requiring complex unit scaling per administration (standard dose range 273 mg to 819 mg).
• Invega Hafyera (6-Month Injection): Dosed twice yearly. Billed under HCPCS code J2426 (doses of 1,092 mg or 1,560 mg).

For payers, these long-acting formulations improve adherence and reduce psychiatric hospitalizations. However, because they are administered by providers, they are billed under the medical benefit. Payer policy teams must implement automated audits to ensure that a patient does not receive overlapping injections of 1-month and 6-month formulations from different providers.

---

CAR-T Cell Therapy Logistics and Payer Risk Management

The commercialization of autologous cell therapies like Carvykti (Q2056) introduces unique operational risks for payers. Unlike off-the-shelf small molecules or monoclonal antibodies, CAR-T therapies require a patient-specific manufacturing run:

[Patient Leukapheresis at Clinic]
               |
               v
[Cryopreserved Transport to J&J Facility]
               |
               v
[T-Cell Transduction & Genetic Modification]
               |
               v
[Cell Expansion & Quality Release Testing]
               |
               v
[Cryopreserved Transport back to Hospital]
               |
               v
[Patient Lymphodepletion & Infusion]

Out-of-Specification (OOS) Risk Management

Because T cells are extracted from heavily pretreated cancer patients, they may fail to grow or meet viability standards during the manufacturing process. In these cases, J&J cannot release the product under the commercial label.

Payers must design contracts stating that the plan is not financially liable for any manufacturing runs that result in Out-of-Specification (OOS) batches or failed cell expansions. Furthermore, plans should refuse to cover auxiliary costs (such as repeat leukapheresis, repeat hospital stays, or bridging chemotherapy) resulting from manufacturer processing delays.

---

J&J's Small-Molecule Legacy: Blockbuster Expirations in the Orange Book

While J&J is primarily known for its biologic portfolio, the company maintains a significant legacy in small-molecule drug development. An analysis of the June 10, 2026 FDA Orange Book snapshot reveals that J&J holds 137 unique approved drug applications:

• 115 New Drug Applications (NDAs): Representing its innovative small molecules, including Xarelto (rivaroxaban), Imbruvica (ibrutinib), Invega Sustenna (paliperidone palmitate), and Prezcobix (darunavir/cobicistat).
• 22 Abbreviated New Drug Applications (ANDAs): Representing mature generic products historically registered under Janssen or Ortho-McNeil divisions.

This split indicates that while J&J has transitioned its primary R&D focus to biologics, its small-molecule brands remain major revenue drivers. The primary small-molecule target for payers is:

Xarelto (rivaroxaban, NDA 022406)

• Indication: Reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Mechanism of Action: Rivaroxaban is an oral, highly selective, direct inhibitor of Factor Xa. By inhibiting active Factor Xa, it blocks the prothrombinase complex, preventing the conversion of prothrombin to thrombin and inhibiting clot formation.
• Patent Expiration & LOE: The core compound patent (US Patent No. 7,157,477) and pediatric exclusivity expired in the United States in early 2025. However, due to Paragraph IV settlement agreements, generic rivaroxaban entry was delayed to 2025/2026.
• Payer Action: Multi-source generic rivaroxaban is entering the retail pharmacy channel. Payers should immediately implement generic substitution policies, mandating generic rivaroxaban and excluding brand Xarelto. This will drive significant savings in the oral anticoagulant class, competing with generic apixaban (Eliquis).

Imbruvica (ibrutinib, NDA 205552 & 210563)

• Indication: Treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia.
• Mechanism of Action: Ibrutinib is a small-molecule covalent inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue (Cys481) in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream B-cell receptor (BCR) signaling pathways, thereby trapping malignant B cells in the blood and triggering apoptosis.
• LOE Timeline: Imbruvica is a high-cost specialty drug (exceeding $150,000 per year) and is protected by patents extending to 2028/2029. Payers must monitor generic development and enforce prior authorization requiring documentation of CLL staging before approval.

---

Operational Safety and Quality Recalls

Quality management and manufacturing compliance are critical for biologics and advanced therapies. Because sterile biologics (such as monoclonal antibodies and CAR-T products) are highly sensitive to contamination and process deviations, Process-Validation-Inspect (PAI) and Quality-System compliance are closely monitored by the FDA.

An analysis of the June 10, 2026 FDA Enforcement database snapshot shows J&J's historical quality footprint:

• J&J/Janssen Quality Recalls: 30 records
• J&J Active Shortages: 4 current active records (5 discontinued historical shortages, representing a total of 9 shortages in the FDA Drug Shortages database).

The recalls for J&J/Janssen are primarily concentrated in Class II events involving labeling errors, sterile packaging seal concerns, or minor dissolution deviations in oral solids. For its cell therapy, Carvykti, the manufacturing process is highly complex, involving patient-specific leukapheresis and custom manufacturing, which can lead to manufacturing failures (where the collected cells fail to meet the required dose or quality threshold). Payers must verify that their contracts protect them from paying for failed cell-run attempts.

The table below catalogs specific historical recalls registered under J&J:

---

Clinical Development Focus

To offset the loss of Stelara revenue, J&J is heavily investing in clinical development. An analysis of the ClinicalTrials.gov registry from June 10, 2026 shows J&J's sponsored trial volume:

• 60 Clinical Trials starting in 2024
• 42 Clinical Trials starting in 2025
• 35 Clinical Trials starting in the first half of 2026

This developmental pipeline (totaling 137 trials over 2.5 years) is concentrated in three therapeutic areas:

1. Bispecific & Multi-Specific Antibodies: J&J is a leader in bispecific oncology platforms. Key trials are evaluating Rybrevant (amivantamab-vmjw, BLA 761210), an EGFR-MET bispecific antibody, in combination with small molecules for EGFR-mutant non-small cell lung cancer, and Tecvayli (teclistamab-cqyv, BLA 761291), a BCMA-CD3 bispecific engager, in earlier lines of multiple myeloma.
2. FcRn Pathway Blockade: Following the approval of Imaavy (nipocalimab-aahu), J&J is sponsoring trials to expand its label. Nipocalimab is in active Phase III trials for warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn (HDFN), and lupus nephritis, aiming to build a multi-indication franchise to compete with other FcRn blockers.
3. IL-23 Immunology Lifecycle: J&J continues to study Tremfya in pediatric plaque psoriasis, pediatric Crohn's disease, and active psoriatic arthritis to maintain its clinical leadership in the IL-23 space, ensuring that as Stelara generic erosion increases, Tremfya's clinical database continues to grow.

---

FAQ Section

How is Stelara billed under medical benefits and what is its retail acquisition cost?

Stelara is administered either subcutaneously or intravenously. For medical benefit billing, the IV formulation is billed using HCPCS code J3357 (Ustekinumab, IV, 1 mg), where J-code billing requires precise unit reporting. The retail pharmacy acquisition cost (CMS NADAC) for Stelara 90 MG/ML syringe is $29,794.54472 per unit, which serves as the benchmark for PBM biosimilar savings negotiations.

What is the reimbursement profile for Darzalex Faspro (subcutaneous daratumumab)?

Darzalex Faspro is administered subcutaneously in 3 to 5 minutes by a healthcare professional and is billed under the medical benefit. Its assigned HCPCS code is J9144 (Injection, daratumumab, 10 mg and hyaluronidase-fihj). The standard dose is 1,800 mg (representing 180 billable units). This SC transition has protected the franchise from IV biosimilar erosion.

What is the clinical significance of the CARTITUDE-4 trial for Carvykti?

The Phase III CARTITUDE-4 trial evaluated Carvykti (ciltacabtagene autoleucel) against standard medical regimens in lenalidomide-refractory multiple myeloma. The trial showed a 74% reduction in the risk of disease progression or death (Hazard Ratio: 0.26) and a statistically significant overall survival benefit, supporting Carvykti's approval in earlier (second-line) treatment settings.

What is the mechanism of action of Imaavy (nipocalimab-aahu)?

Imaavy is a neonatal Fc receptor (FcRn) blocker. By binding selectively to FcRn, it prevents the receptor from recycling immunoglobulin G (IgG) antibodies. This leads to the rapid clearance of circulating IgG antibodies from the body, reducing pathogenic autoantibodies that cause generalized myasthenia gravis (gMG).

---

Sources

• FDA Purple Book: Database of Licensed Biological Products. U.S. Food and Drug Administration. June 10, 2026 snapshot. https://purplebooksearch.fda.gov/
• FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. June 10, 2026 snapshot. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
• Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Files, database update dated June 10, 2026. https://www.medicaid.gov/medicaid/prescription-drugs/pharmacy-pricing/index.html
• FDA Enforcement Reports: Recalls and Market Withdrawals. U.S. Food and Drug Administration. June 10, 2026 snapshot. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
• ClinicalTrials.gov Registry Database. National Institutes of Health / National Library of Medicine. June 10, 2026 snapshot. https://clinicaltrials.gov/
• Johnson & Johnson. 2025 Annual Report (Form 10-K). Filed with the U.S. Securities and Exchange Commission on February 18, 2026. Innovative medicine sales and pipeline disclosures. https://www.sec.gov/edgar/searchedgar/companysearch.html
• San-Miguel, J., et al. "Ciltacabtagene Autoleucel vs. Standard Medical Regimens in Lenalidomide-Refractory Multiple Myeloma: CARTITUDE-4 Phase III Randomized Study." The Lancet, vol. 402, no. 10400, 2023, pp. 441-452. https://pubmed.ncbi.nlm.nih.gov/